250 related articles for article (PubMed ID: 35920742)
1. Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing.
Hiatt JB; Sandborg H; Garrison SM; Arnold HU; Liao SY; Norton JP; Friesen TJ; Wu F; Sutherland KD; Rienhoff HY; Martins R; Houghton AM; Srivastava S; MacPherson D
Clin Cancer Res; 2022 Oct; 28(20):4551-4564. PubMed ID: 35920742
[TBL] [Abstract][Full Text] [Related]
2. Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC.
Nguyen EM; Taniguchi H; Chan JM; Zhan YA; Chen X; Qiu J; de Stanchina E; Allaj V; Shah NS; Uddin F; Manoj P; Liu M; Cai SF; Levine R; Quintanal-Villalonga Á; Sen T; Chow A; Rudin CM
J Thorac Oncol; 2022 Aug; 17(8):1014-1031. PubMed ID: 35691495
[TBL] [Abstract][Full Text] [Related]
3. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
[TBL] [Abstract][Full Text] [Related]
4. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.
Taniguchi H; Caeser R; Chavan SS; Zhan YA; Chow A; Manoj P; Uddin F; Kitai H; Qu R; Hayatt O; Shah NS; Quintanal Villalonga Á; Allaj V; Nguyen EM; Chan J; Michel AO; Mukae H; de Stanchina E; Rudin CM; Sen T
Cell Rep; 2022 May; 39(7):110814. PubMed ID: 35584676
[TBL] [Abstract][Full Text] [Related]
5. Role of CD38 in anti-tumor immunity of small cell lung cancer.
Taniguchi H; Chavan SS; Chow A; Chan JM; Mukae H; Rudin CM; Sen T
Front Immunol; 2024; 15():1348982. PubMed ID: 38533509
[TBL] [Abstract][Full Text] [Related]
6. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
Xue L; Chen B; Lin J; Peng J
Ann Palliat Med; 2021 Jan; 10(1):828-835. PubMed ID: 33545805
[TBL] [Abstract][Full Text] [Related]
8. LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B.
Takagi S; Ishikawa Y; Mizutani A; Iwasaki S; Matsumoto S; Kamada Y; Nomura T; Nakamura K
Cancer Res; 2017 Sep; 77(17):4652-4662. PubMed ID: 28667074
[TBL] [Abstract][Full Text] [Related]
9. Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC.
Sen T; Della Corte CM; Milutinovic S; Cardnell RJ; Diao L; Ramkumar K; Gay CM; Stewart CA; Fan Y; Shen L; Hansen RJ; Strouse B; Hedrick MP; Hassig CA; Heymach JV; Wang J; Byers LA
J Thorac Oncol; 2019 Dec; 14(12):2152-2163. PubMed ID: 31470128
[TBL] [Abstract][Full Text] [Related]
10. Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer.
Roper N; Velez MJ; Chiappori A; Kim YS; Wei JS; Sindiri S; Takahashi N; Mulford D; Kumar S; Ylaya K; Trindade C; Manukyan I; Brown AL; Trepel JB; Lee JM; Hewitt S; Khan J; Thomas A
Nat Commun; 2021 Jun; 12(1):3880. PubMed ID: 34162872
[TBL] [Abstract][Full Text] [Related]
11. Targeting LSD1 suppresses stem cell-like properties and sensitizes head and neck squamous cell carcinoma to PD-1 blockade.
Han Y; Xu S; Ye W; Wang Y; Zhang X; Deng J; Zhang Z; Liu L; Liu S
Cell Death Dis; 2021 Oct; 12(11):993. PubMed ID: 34689153
[TBL] [Abstract][Full Text] [Related]
12. Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models.
Jasmine S; Mandl A; Krueger TEG; Dalrymple SL; Antony L; Dias J; Celatka CA; Tapper AE; Kleppe M; Kanayama M; Jing Y; Speranzini V; Wang YZ; Luo J; Trock BJ; Denmeade SR; Carducci MA; Mattevi A; Rienhoff HY; Isaacs JT; Nathaniel Brennen W
Prostate; 2024 Apr; ():. PubMed ID: 38619005
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4-driven transcriptional state.
Yan W; Chung CY; Xie T; Ozeck M; Nichols TC; Frey J; Udyavar AR; Sharma S; Paul TA
Mol Oncol; 2022 Mar; 16(6):1309-1328. PubMed ID: 34669238
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity.
Mahadevan NR; Knelson EH; Wolff JO; Vajdi A; Saigí M; Campisi M; Hong D; Thai TC; Piel B; Han S; Reinhold BB; Duke-Cohan JS; Poitras MJ; Taus LJ; Lizotte PH; Portell A; Quadros V; Santucci AD; Murayama T; Cañadas I; Kitajima S; Akitsu A; Fridrikh M; Watanabe H; Reardon B; Gokhale PC; Paweletz CP; Awad MM; Van Allen EM; Lako A; Wang XT; Chen B; Hong F; Sholl LM; Tolstorukov MY; Pfaff K; Jänne PA; Gjini E; Edwards R; Rodig S; Reinherz EL; Oser MG; Barbie DA
Cancer Discov; 2021 Aug; 11(8):1952-1969. PubMed ID: 33707236
[TBL] [Abstract][Full Text] [Related]
15. Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1.
Chen HY; Durmaz YT; Li Y; Sabet AH; Vajdi A; Denize T; Walton E; Laimon YN; Doench JG; Mahadevan NR; Losman JA; Barbie DA; Tolstorukov MY; Rudin CM; Sen T; Signoretti S; Oser MG
Nat Commun; 2022 Aug; 13(1):4998. PubMed ID: 36008402
[TBL] [Abstract][Full Text] [Related]
16. Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations.
Macheleidt IF; Dalvi PS; Lim SY; Meemboor S; Meder L; Käsgen O; Müller M; Kleemann K; Wang L; Nürnberg P; Rüsseler V; Schäfer SC; Mahabir E; Büttner R; Odenthal M
Mol Oncol; 2018 Nov; 12(11):1965-1979. PubMed ID: 30220105
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function.
Dowlati A; Abbas A; Chan T; Henick B; Wang X; Doshi P; Fu P; Patel J; Kuo F; Chang H; Balli D
JCO Precis Oncol; 2022 Aug; 6():e2200257. PubMed ID: 36044718
[TBL] [Abstract][Full Text] [Related]
18. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.
Lai AY; Sorrentino JA; Dragnev KH; Weiss JM; Owonikoko TK; Rytlewski JA; Hood J; Yang Z; Malik RK; Strum JC; Roberts PJ
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33004541
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous Inhibition of LSD1 and TGFβ Enables Eradication of Poorly Immunogenic Tumors with Anti-PD-1 Treatment.
Sheng W; Liu Y; Chakraborty D; Debo B; Shi Y
Cancer Discov; 2021 Aug; 11(8):1970-1981. PubMed ID: 33687985
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study.
Thomas A; Vilimas R; Trindade C; Erwin-Cohen R; Roper N; Xi L; Krishnasamy V; Levy E; Mammen A; Nichols S; Chen Y; Velcheti V; Yin F; Szabo E; Pommier Y; Steinberg SM; Trepel JB; Raffeld M; Young HA; Khan J; Hewitt S; Lee JM
J Thorac Oncol; 2019 Aug; 14(8):1447-1457. PubMed ID: 31063862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
